Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
9 studies found for:    17021319 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Drug: Ranibizumab (Lucentis)
2 Recruiting Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.
Condition: Radiation Retinopathy
Interventions: Drug: 0.5 mg ranibizumab;   Procedure: Targeted Retinal Photocoagulation
3 Completed
Has Results
Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
Condition: Exudative Age-related Macular Degeneration
Intervention: Drug: ranibizumab
4 Active, not recruiting Study for Recalcitrant Age Related Macular Degeneration
Condition: Age Related Macular Degeneration
Intervention: Drug: aflibercept 2.0 mg
5 Recruiting Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
Conditions: Exudative Age-related Macular Degeneration;   Polypoidal Choroidal Vasculopathy
Intervention: Drug: aflibercept
6 Recruiting Proton Radiation Therapy for Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Radiation: Proton radiation
7 Active, not recruiting Treat and Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab
Condition: Macular Degeneration
Intervention: Drug: 0.5mg ranibizumab
8 Completed A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: rhuFab V2 (ranibizumab)
9 Unknown  Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration
Conditions: Macular Degeneration;   Visual Acuity
Intervention: Drug: Ranibizumab

Indicates status has not been verified in more than two years